📊 CLSDQ Key Takeaways
Is Clearside Biomedical, Inc. (CLSDQ) a Good Investment?
Clearside Biomedical faces severe financial distress with negative stockholders' equity of -$54.0M, indicating liabilities exceed assets by a significant margin. The company is burning cash rapidly with -$16.0M operating cash flow against only $6.8M in cash reserves, providing minimal runway. Revenue has collapsed 79.8% YoY while operating losses exceed -$15.8M, demonstrating a non-viable business model at current scale.
Clearside Biomedical’s fundamentals are severely impaired: revenue fell 79.8% year over year while operating and free cash flow remain deeply negative, indicating the business is not close to self-funding. The balance sheet is especially weak, with negative stockholders’ equity and liabilities far exceeding assets, so despite an adequate current ratio, the company appears highly dependent on external financing or restructuring to sustain operations.
Why Buy Clearside Biomedical, Inc. Stock? CLSDQ Key Strengths
- Current ratio of 2.98x provides short-term liquidity buffer despite negative equity
- Relatively low long-term debt of $385.0K limits additional leverage burden
- Pharmaceutical sector positioning in specialized treatments if development succeeds
- Cash of $6.80M and a 2.98x current ratio provide limited near-term liquidity support
- Low reported long-term debt of $385K reduces traditional debt-servicing pressure
- EPS loss improved year over year, suggesting some per-share loss moderation
CLSDQ Stock Risks: Clearside Biomedical, Inc. Investment Risks
- Negative stockholders' equity of -$54.0M indicates technical insolvency and high bankruptcy risk
- Cash burn rate of -$16.0M annually against $6.8M cash implies runway of less than 5 months
- Severe revenue decline of -79.8% YoY signals complete loss of commercial traction
- Negative operating margin of -523.1% and net margin of -618.3% demonstrate unsustainable unit economics
- Zero insider buying in last 90 days and no evidence of strategic confidence
- Revenue collapse of 79.8% indicates very weak and potentially unstable commercial traction
- Operating margin of -523.1% and free cash flow of -$16.05M show an unsustainable cost structure
- Negative stockholders’ equity of -$53.95M reflects severe balance-sheet stress and elevated financing risk
Key Metrics to Watch
- Monthly cash burn rate and cash position deterioration
- Revenue stabilization or evidence of new commercial contracts
- Stockholders' equity trajectory and capital restructuring plans
- Operating cash flow improvement toward sustainability threshold
- Quarterly revenue stabilization or renewed growth
- Cash burn relative to cash balance and any changes in stockholders’ equity
Clearside Biomedical, Inc. (CLSDQ) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.98x current ratio provides a solid financial cushion.
CLSDQ Profit Margin, ROE & Profitability Analysis
CLSDQ vs Healthcare Sector: How Clearside Biomedical, Inc. Compares
How Clearside Biomedical, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Clearside Biomedical, Inc. Stock Overvalued? CLSDQ Valuation Analysis 2026
Based on fundamental analysis, Clearside Biomedical, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Clearside Biomedical, Inc. Balance Sheet: CLSDQ Debt, Cash & Liquidity
CLSDQ Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Clearside Biomedical, Inc.'s revenue has shown modest growth of 4% over the 5-year period. The most recent EPS of $-0.55 indicates the company is currently unprofitable.
CLSDQ Revenue Growth, EPS Growth & YoY Performance
CLSDQ Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $201.0K | -$4.5M | $-1.14 |
| Q2 2025 | $90.0K | -$4.5M | $-0.06 |
| Q1 2025 | $230.0K | -$8.2M | $-0.11 |
| Q3 2024 | $859.0K | -$7.6M | $-0.10 |
| Q2 2024 | $90.0K | -$7.6M | $-0.10 |
| Q1 2024 | $4.0K | -$9.3M | $-0.15 |
| Q3 2023 | $266.0K | -$7.6M | $-0.13 |
| Q2 2023 | $384.0K | -$7.6M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Clearside Biomedical, Inc. Dividends, Buybacks & Capital Allocation
CLSDQ SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Clearside Biomedical, Inc. (CIK: 0001539029)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLSDQ
What is the AI rating for CLSDQ?
Clearside Biomedical, Inc. (CLSDQ) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLSDQ's key strengths?
Claude: Current ratio of 2.98x provides short-term liquidity buffer despite negative equity. Relatively low long-term debt of $385.0K limits additional leverage burden. ChatGPT: Cash of $6.80M and a 2.98x current ratio provide limited near-term liquidity support. Low reported long-term debt of $385K reduces traditional debt-servicing pressure.
What are the risks of investing in CLSDQ?
Claude: Negative stockholders' equity of -$54.0M indicates technical insolvency and high bankruptcy risk. Cash burn rate of -$16.0M annually against $6.8M cash implies runway of less than 5 months. ChatGPT: Revenue collapse of 79.8% indicates very weak and potentially unstable commercial traction. Operating margin of -523.1% and free cash flow of -$16.05M show an unsustainable cost structure.
What is CLSDQ's revenue and growth?
Clearside Biomedical, Inc. reported revenue of $3.0M.
Does CLSDQ pay dividends?
Clearside Biomedical, Inc. does not currently pay dividends.
Where can I find CLSDQ SEC filings?
Official SEC filings for Clearside Biomedical, Inc. (CIK: 0001539029) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLSDQ's EPS?
Clearside Biomedical, Inc. has a diluted EPS of $-3.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CLSDQ a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Clearside Biomedical, Inc. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CLSDQ stock overvalued or undervalued?
Valuation metrics for CLSDQ: ROE of N/A (sector avg: 15%), net margin of -618.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CLSDQ stock in 2026?
Our dual AI analysis gives Clearside Biomedical, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLSDQ's free cash flow?
Clearside Biomedical, Inc.'s operating cash flow is $-16.0M, with capital expenditures of $9.0K. FCF margin is -530.9%.
How does CLSDQ compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -618.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.98 (avg: 2).